Joris Wilms - 26 Jan 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
SVP & CHIEF OPERATING OFFICER
Signature
/s/ Sune Reinholth Nyland, Attorney-in-Fact for Joris Wilms
Issuer symbol
YMAB
Transactions as of
26 Jan 2023
Transactions value $
$0
Form type
4
Filing time
30 Jan 2023, 15:31:17
Previous filing
19 Jan 2023
Next filing
22 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +32K $0.00 32K 26 Jan 2023 Common stock 32K $4.55 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F2 The stock option shall vest and become exercisable as to 25% of the shares subject to the option on January 26, 2024, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting.

Remarks:

Exhibit Index: Exhibit 24 - Power of Attorney for Joris Wilms dated December 5, 2022.